10 December 2021 - It was the day before Christmas in 2015 and a senior director of national accounts at Novo Nordisk, one of the biggest makers of diabetes medicines, was excited about what Santa might bring.
Eli Lilly had just raised the wholesale price for a diabetes drug, and the employee was hopeful that yet another rival would do the same.